Chase Doyle

Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer.

Phase III results of the KRISTINE trial demonstrated that patients with HER2-positive early breast cancer had a significantly higher pathological complete response (pCR) rate when they received the neoadjuvant regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCH+P) versus trastuzumab emtansine (T-DM1) plus pertuzumab (T-DM1+P).  

In patients with HER2-positive early breast cancer, data from a phase III trial has shown a significantly higher pathological complete response (pCR) rate with neoadjuvant docetaxel plus carboplatin plus trastuzumab plus pertuzumab versus trastuzumab emtansine plus pertuzumab.

Interim analysis of a clinical trial of multiplex gene testing for inherited cancer risk suggests that fears of unnecessary surgery or adverse psychological effects associated with testing may be unwarranted.

A joint analysis of the "ABC" trials comparing anthracycline versus non-anthracycline treatment in patients with high-risk, HER2-negative breast cancer has failed to demonstrate non-inferiority of the non-anthracycline regimen.

A combination of venetoclax and obinutuzumab, followed by additional cycles of venetoclax, has shown tolerability in elderly patients with previously untreated chronic lymphocytic leukemia with comorbidities, data from the CLL14 trial (BO25323) shows.

The combination of selective internal radiation therapy (SIRT) with first-line chemotherapy showed a 31% reduction in the risk of disease progression within the liver of patients with metastatic colorectal cancer (mCRC) compared with chemotherapy alone.

Tumor treating fields (TTFields) significantly and consistently prolonged both progression free survival (PFS) and overall survival (OS) in a randomized, phase III trial of patients with glioblastoma.

In the largest patient population study to date, Mayo Clinic investigators have identified new genetic predictors of toxicity to colon cancer treatment, but the study has some caveats.

An analysis of patients with advanced hepatocellular carcinom and elevated α-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.